Skip to main content
U.S. flag

An official website of the United States government

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Search help
1,333 results
  1. New MeSH Descriptor: Severe Acute Respiratory Syndrome (SARS). NLM Technical Bulletin. 2003 Mar-Apr 
    https://www.nlm.nih.gov/pubs/techbull/ma03/ma03_sars.html
    ... addition] New MeSH Descriptor: Severe Acute Respiratory Syndrome (SARS) he MeSH Section announces the addition of a ... RESPIRATORY DISTRESS SYNDROME, ADULT; do not confuse abbreviation, SARS, with SAR used for STRUCTURE-ACTIVITY RELATIONSHIP or ...
  2. NLM Reassigns Status of 242 SARS-CoV-2 Sequences in the Sequence Read Archive. NLM Technical Bulletin. 2022 Mar–Apr 
    https://www.nlm.nih.gov/pubs/techbull/ma22/ma22_nlm_sra.html
    ... 445 Previous Next NLM Reassigns Status of 242 SARS-CoV-2 Sequences in the Sequence Read Archive NLM Reassigns Status of 242 SARS-CoV-2 Sequences in the Sequence Read Archive. ...
  3. MedlinePlus Drug Information: Tocilizumab Injection 
    https://medlineplus.gov/druginfo/meds/a611004.html
    ... disease 2019 (COVID-19 infection) caused by the SARS-CoV-2 virus in hospitalized adults who require ...
  4. NLM Digital Collections - Variation in use of anti-SARS-CoV-2 monoclonal antibody therapies by social vulnerability and ... 
    Publication: Washington, DC : Office of the Assistant Secretary for Planning and Evaluation, Office of Science & Data Policy, December 2021
    resource.nlm.nih.gov/9918538381206676
    Variation in use of anti-SARS-CoV-2 monoclonal antibody therapies by social vulnerability and urbanicity ... Anti-SARS-CoV-2 monoclonal antibodies are an effective treatment to prevent progression to severe COVID-19 or hospitalization ...
  5. NLM Digital Collections - Development of monoclonal antibody products targeting SARS-CoV-2 for emergency use ... 
    Publication: Silver Spring, MD : Center for Drug Evaluation and Research, December 2023
    resource.nlm.nih.gov/9918751183806676
    Development of monoclonal antibody products targeting SARS-CoV-2 for emergency use authorization : guidance for industry ... SARS-CoV-2 ... the development of monoclonal antibody (mAb) products targeting SARS-CoV-2 intended for the prevention or treatment ...
  6. NLM Digital Collections - Boenninghausen's therapeutic pocket book for homoeopathic physicians to use at the bedside ... 
    Publication: Philadelphia : Hahnemann Pub. House, 1891
    resource.nlm.nih.gov/100889133
    ... Op, Petrol, Plat, Pb, Rhus, Buta, Saba, Sabi, Sars, Seneg, Sep, SIL, Spo, Squ, Stan, Staph, SUL, ... Ran. s. Rheum, Rhodo, Rhus, Ruta, Sabi, Sal. ae, Sars, Sec c, Sep, SIL, Spig, Squ, S'taph, Still, ...
  7. xmlmplus_topics_2025-04-18.xml 
    https://medlineplus.gov/xml/mplus_topics_2025-04-18.xml
    ... 19 post-agudo y secuelas post-agudas de SARS-CoV-2 (SPAC).</p> <h3>¿Quién tiene más ... a virus. This virus is a coronavirus called SARS-CoV-2. It spreads when a person who ...
  8. Excluded Studies List - Long COVID Models of Care - NCBI Bookshelf 
    https://www.ncbi.nlm.nih.gov/books/NBK603661
    ... Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nature Medicine. 2022 07;28( ... dysfunction in patients with post-acute sequelae of SARS-CoV-2 infection (PASC). PM&R. 2022 Oct; ...
  9. pdfSummer03.pdf 
    https://www.ncbi.nlm.nih.gov/books/NBK2592/bin/Summer03.pdf
    ... UniGene cluster sequences that map to the region. SARS Coronavirus Resource The first complete sequence of the SARS Coronavirus, determined by the BC Cancer Agency Genome ...
  10. pdfBSC_10_15_16_2020_minutes.pdf 
    https://www.nlm.nih.gov/.../BSC_10_15_16_2020_minutes.pdf
    ... PhD, Koonin group – Genomic determinants of pathogenicity in SARS- CoV-2 and human coronaviruses • Nash Rochman, PhD, ... IEB) over the last year, including COVID-19/SARS-CoV-2 activities. Highlights they presented included: • NCBI ...
first · previous · 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · next · last